NASDAQ: EWTX
Edgewise Therapeutics Inc Stock

$25.39-0.63 (-2.42%)
Updated Feb 14, 2025
EWTX Price
$25.39
Fair Value Price
$1.27
Market Cap
$2.40B
52 Week Low
$14.90
52 Week High
$38.12
P/E
-16.93x
P/B
4.92x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$124.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$109M
Beta
1.44
Next Earnings
Feb 20, 2025
Ex-Dividend
N/A
Next Dividend
N/A

EWTX Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, is developing small molecule therapies for musculoskeletal diseases. The company's product candidates target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics was incorporated in 2017 and is headquartered in Boulder, CO.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine EWTX's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
EWTX
Ranked
#327 of 561

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important EWTX news, forecast changes, insider trades & much more!

EWTX News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EWTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EWTX ($25.39) is overvalued by 1,905.31% relative to our estimate of its Fair Value price of $1.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EWTX ($25.39) is not significantly undervalued (1,905.31%) relative to our estimate of its Fair Value price of $1.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EWTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EWTX due diligence checks available for Premium users.

Valuation

EWTX fair value

Fair Value of EWTX stock based on Discounted Cash Flow (DCF)

Price
$25.39
Fair Value
$1.27
Overvalued by
1,905.31%
EWTX ($25.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EWTX ($25.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EWTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

EWTX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-16.93x
Industry
-169.22x
Market
37.91x

EWTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.92x
Industry
4.77x
EWTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

EWTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$34.1M
Profit Margin
0%
EWTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$511.3M
Liabilities
$22.4M
Debt to equity
0.05
EWTX's short-term assets ($499.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EWTX's short-term assets ($499.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EWTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$27.4M
Investing
$25.4M
Financing
$3.3M
EWTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

EWTX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
EWTXD$2.40B-2.42%-16.93x4.92x
MIRMB$2.40B-1.30%-24.06x10.35x
KYMRF$2.39B+0.68%-15.76x2.67x
PTGXC$2.30B-0.03%13.38x4.33x
ARWRC$2.52B+4.40%-3.87x47.84x

Edgewise Therapeutics Stock FAQ

What is Edgewise Therapeutics's quote symbol?

(NASDAQ: EWTX) Edgewise Therapeutics trades on the NASDAQ under the ticker symbol EWTX. Edgewise Therapeutics stock quotes can also be displayed as NASDAQ: EWTX.

If you're new to stock investing, here's how to buy Edgewise Therapeutics stock.

What is the 52 week high and low for Edgewise Therapeutics (NASDAQ: EWTX)?

(NASDAQ: EWTX) Edgewise Therapeutics's 52-week high was $38.12, and its 52-week low was $14.90. It is currently -33.39% from its 52-week high and 70.4% from its 52-week low.

How much is Edgewise Therapeutics stock worth today?

(NASDAQ: EWTX) Edgewise Therapeutics currently has 94,688,517 outstanding shares. With Edgewise Therapeutics stock trading at $25.39 per share, the total value of Edgewise Therapeutics stock (market capitalization) is $2.40B.

Edgewise Therapeutics stock was originally listed at a price of $35.99 in Mar 29, 2021. If you had invested in Edgewise Therapeutics stock at $35.99, your return over the last 3 years would have been -29.45%, for an annualized return of -10.98% (not including any dividends or dividend reinvestments).

How much is Edgewise Therapeutics's stock price per share?

(NASDAQ: EWTX) Edgewise Therapeutics stock price per share is $25.39 today (as of Feb 14, 2025).

What is Edgewise Therapeutics's Market Cap?

(NASDAQ: EWTX) Edgewise Therapeutics's market cap is $2.40B, as of Feb 18, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Edgewise Therapeutics's market cap is calculated by multiplying EWTX's current stock price of $25.39 by EWTX's total outstanding shares of 94,688,517.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.